[108] Pfeiffer F, Rosenthal M, Siegl J, Ewers J, Mayer G. Customised nucleic acid libraries for enhanced aptamer selection and performance. Curr Opin Biotechnol. 2017 Apr 21; 48:111-118.

[107] Toulme JJ, Giangrande PH, Mayer G, Suess B, Duconge F, Sullenger B, de Franciscis V, Darfeuille F, Peyrin E. Aptamers in Bordeaux, 24-25 June 2016. Pharmaceuticals (Basel). 2017 Jan 20; 10(1).

[106] Wolter O, Mayer G. Aptamers as Valuable Molecular Tools in Neurosciences. J Neurosci. 2017 Mar 8; 37(10):2517-2523.

[105] Domenyuk V, Zhong Z, Stark A, Xiao N, O’Neill HA, Wei X, Wang J, Tinder TT, Tonapi S, Duncan J, Hornung T, Hunter A, Miglarese MR, Schorr J, Halbert DD, Quackenbush J, Poste G, Berry DA, Mayer G, Famulok M, Spetzler D. Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach. Sci. Rep. 2017 Feb 20; 7:42741.

[104] Lünse CE, Mayer G. Reporter Gene-Based Screening for TPP Riboswitch Activators. Methods Mol Biol. 2017; 1520:227-235.

[103] Seyfried P, Eiden L, Grebenovsky N, Mayer G, Heckel A. Photo-Tethers for the (Multi-)Cyclic, Conformational Caging of Long Oligonucleotides. Angew Chem Int Ed Engl. 2017 Jan 2; 56(1):359-363.

[102] Hamedani NS, Rühl H, Zimmermann JJ, Heiseler T, Oldenburg J, Mayer G, Pötzsch B, Müller J. In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. Nucleic Acid Ther. 2016 Dec; 26(6):355-362.

[101] Mayer G, Schüller A, Matzner D, Lünse C, Wittmann V, Schumacher C, Unsleber S, Brötz-Oesterhelt H, Mayer C, Bierbaum G. Activation of the glmS ribozyme confers bacterial growth inhibition. Chembiochem. 2016 Dec 24. [Epub ahead of print]

[100] Pfeiffer F, Mayer G. Selection and Biosensor Application of Aptamers for Small Molecules. Front Chem. 2016 Jun 15; 4:25.

[99] Mayer G, Tolle F, Pfeiffer F, Rosenthal M. Click reaction on solid phase enables high fidelity synthesis of nucleobase-modified DNA. Bioconjug Chem. 2016 Feb 5.

[98] Jauset Rubio M, Svobodová M, Mairal T, Schubert T, Künne S, Mayer G, O'Sullivan CK. β-Conglutin dual aptamers binding distinct aptatopes. Anal BioanalChem. 2016 Jan; 408(3):875-84.

[97] Müller J, Becher T, Mayer G, Pötzsch B. Aptamer-Based Enzyme Capture Assay for Measurement of Plasma Thrombin Levels. Methods Mol Biol. 2016; 1380:179-89.

[96] Tolle F, Mayer G. Preparation of SELEX Samples for Next-Generation Sequencing. Methods Mol Biol. 2016; 1380:77-84.

[95] Long Y, Pfeiffer F, Mayer G, Schrøder TD, Özalp VC, Olsen LF. Selection of Aptamers for Metabolite Sensing and Construction of Optical Nanosensors. Methods Mol Biol. 2016; 1380:3-19.

[94] Civit L, Pinto A, Rodrigues-Correia A, Heckel A, O'Sullivan CK, Mayer G. Sensitive detection of cancer cells using light-mediated apta-PCR. Methods2015 Nov 23. pii: S1046-2023(15)30158-4.

[93]Tolle F, Brändle GM, Matzner D, Mayer G. A Versatile Approach Towards Nucleobase-Modified Aptamers. Angew Chem Int Ed Engl. 2015 Sep 7; 54(37):10971-4.

[92] Opazo F, Eiden L, Hansen L, Rohrbach F, Wengel J, Kjems J, Mayer G. Modular Assembly of Cell-targeting Devices Based on an Uncommon G-quadruplex Aptamer. MolTher Nucleic Acids. 2015 Sep 1; 4:e251.

[91] Dickinson H, Lukasser M, Mayer G, Hüttenhofer A. Cell-SELEX: in vitro selection of synthetic small specific ligands. Methods Mol Biol. 2015; 1296:213-24.

[90] Lennarz S, Alich TC, Kelly T, Blind M, Beck H, Mayer G. Selective aptamer-based control of intraneuronal signaling. Angew Chem Int Ed Engl. 2015 Apr 27; 54(18):5369-73.

[89] Matzner D, Mayer G. (Dis)similar Analogues of Riboswitch Metabolites as Antibacterial Lead Compounds. J Med Chem. 2015 Apr 23; 58(8):3275-86.

[88] Tolle F, Wilke J, Wengel J, Mayer G. By-product formation in repetitive PCR amplification of DNA libraries during SELEX. PLoS One. 2014 Dec 9; 9(12):e114693.

[87] Hamedani NS, Blümke F, Tolle F, Rohrbach F, Rühl H, Oldenburg J, Mayer G, Pötzsch B, Müller J. Capture and Release (CaR): a simplified procedure forone-tube isolation and concentration of single-stranded DNA during SELEX. ChemCommun (Camb). 2015 Jan 21; 51(6):1135-8.

[86] Famulok M, Mayer G. Aptamers and SELEX in Chemistry & Biology. Chem Biol2014 Sep 18; 21(9):1055-8.

 

[85] Lünse CE, Scott FJ, Suckling CJ, and Mayer G. Novel TPP-riboswitch activators bypass metabolic enzyme dependency. Front. Chem., 2014, 2, 53

[84] Lennarz S, Heider E, Blind M, and Mayer G. An aptamer to the MAP kinase insert region. ACS Chem. Biol., 2014, in print.

[83] Famulok M and Mayer G. Aptamers and SELEX in Chemistry & Biology. Chem. Biol., 2014, 18, 1055-1058.

[82] Pofahl M, Wengel J, and Mayer G. Multifunctional nucleic acids for tumour cell treatment. Nucleic Acid Ther., 2014, 24, 171-177.

[81] Yassin AA, Elwaseef AM, Elnashar M, Oldenburg J, Mayer G, Pötzsch B, and Müller J. Protamine-adsorbed magnetic nanoparticles for efficient isolation and concentration of hepatitis-C virus from human plasma samples. Chem. Com., 2014, 50, 590-592.

[80] Rohrbach F, Schäfer F, Fichte MAH, Pfeiffer F, Müller J, Pötzsch B, Heckel A, and Mayer G. Aptamer-guided caging for selective masking of protein domains. Angew. Chem. Int. Ed., 2013, 52, 1912-5

[79] Mayer G, Pofahl M, Schöler KMU, and Haßel S. Cell-specific aptamers for nano-medical applications. Nucleic Acid Nanotechnology, Springer-Verlag (Ed. J. Kjems), 2013.

[78] Lünse CE, Schüller A, and Mayer G. The promise of riboswitches as potential antibacterial drug targets. Int. J. Med. Microbiol.2014, 304, 79-92.

[77] Hussein M, Bettio M, Schmitz A, Hannam JS, Theis J, Mayer G, Dosa S, Gütschow M, and Famulok M. Cyplecksins are covalent cytohesin pleckstrin homology domain inhibitors. Angew. Chem. Int. Ed.2013,52, 9529-9533.

[76] Lünse CE & Mayer G. Screening assays to identify artificial glmS ribozyme activators. Meth. In Mol. Biol.2014, Springer ProtocolsHumana Press Ltd. (Ed. Lafontaine).

[75] Magbanua E, Zivkovic T, Hansen B, Beschorner N, Meyer C, Lorenzen I, Grötzinger J, Hauber J, Torda A, Mayer G, Rose-John S, and Hahn U. d(GGGT)4 and r(GGGU)4 are both HIV-1 Inhibitors and Interleukin-6 Receptor Aptamers. RNA Biology2012, 10, 216-227.

[74] Lentz CS, Halls V, Hannam JS, Niebel B, Strübing U, Mayer G, Hoerauf A, Famulok M, and Pfarr K. A selective inhibitor of heme biosynthesis in endosymbiotic bacteria elicits antifilarial activity in vitro. Chem. Biol.2013, 20, 177-187.

[73] Tolle F and Mayer G. Dressed for success - Applying chemistry to modulate aptamer functionality. Chem. Sci.2013, 4, 60-67.

[72] Vinkenborg J, Mayer G, and Famulok M. Aptamer-based affinity labeling of proteins, Angew. Chem. Int. Ed.2012, 51, 9176-9180.

[71] Brieke C, Rohrbach F, Gottschalk A*, Mayer G*, and Heckel A*.  Light tools. Angew. Chem. Int. Ed.2012, 51, 8446-8476.

[70] Rohrbach F, Fathalla MI, Kupper T, Pötzsch B, Müller J, Petersen M, Pedersen EB, and Mayer G. Chemical maturation of a bivalent aptamer by single domain variation. ChemBioChem2012, 13, 631-634.

[69] Rühl H, Müller J, Fimmers R, Harbrecht U, Oldenburg J, Mayer G, and Pötzsch B. Thrombin inhibition profiles in healthy individuals and thrombophilic patients. Thrombosis & Haemostasis2012, 107, 848-853.

[68] Tesmer VM, Lennarz S, Mayer G*, and Tesmer JJG*. Molecular mechanism for inhibition of G-protein coupled receptor kinase 2 by a selective RNA aptamer. Structure2012, 20, 1300-1309.

[67] Pinto A, Lennarz S, Rodrigues-Correia A, Heckel A, O’Sullivan CK, andMayer G. Functional detection of proteins with caged aptamers, ACS Chem. Biol., 2012, 7, 360-366.

[66] Meyer C, Eydeler K, Magbanua E, Zivkovic T, Piganeau N, Lorenzen I, Grötzinger J, Mayer G, Rose-John S, and Hahn U. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biol.2012, 9, 67-80.

[65] Müller J, Becher T, Braunstein J, Berdel P, Gravius S, Rohrbach F, Oldenburg J, Mayer G,* and Pötzsch B*. Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay (OECA), J. Thromb. Haemost.2012, 10, 390-398.

[64] Rohrbach F, Karadeniz H, Erdem A*, Famulok M, and Mayer G*. Label-free Impedimetric Aptasensor for Lysozyme Detection Based on Carbon Nanotube Modified Screen Printed Electrodes. Anal. Biochem., 2012, 421, 454-459.

[63] Wulffen B, Buff MC, Pofahl M, Mayer G*, and Heckel A*. Caged glucosamine-6-phosphate for the light-control of riboswitch activity.Photochem. Photobiol. Sci.2012, 11, 489-492.

[62] Mayer G, Lennarz S, Rohrbach F, and Tolle F. Plug and Play with RNA.Angew. Chem. Int. Ed.2011, 50, 12400-1.

[61] Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone JA, Barry SC, Sparwasser T, Riley JL, Schultze J. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat. Immunol.2011, 12, 898-907.

[60] Famulok M & Mayer G. Aptamer modules as sensors and detectors.Acc. Chem. Res.2011, 44, 1349-58.

[59] Mayer G, Rohrbach F, Pötzsch B, and Müller J. Aptamer-based modulation of blood coagulation. Hämostaseologie2011, 31, 258-63.

[58] Lünse CE, Schmidt M, Wittmann V, and Mayer G. Carba-sugars activate the glmS-riboswitch from Staphylococcus aureusACS Chem. Biol., 2011, 6, 675-678.

[57] Müller J, Becher T, Braunstein J, Berdel P, Gravius S, Rohrbach F, Oldenburg J, Mayer G,* and Pötzsch B*. Profiling of in vivo thrombin activity via supramolecular complexes. Angew. Chem. Int. Ed.2011, 50, 6075-8.

[56] Mayer G, Müller J, and Lünse CE. RNA diagnostic - Real-time RT-PCR strategies and promising novel target RNAs. RNA Wire2010, 2, 32-41.

[55] Niebel B, Lentz C, Pofahl M, Mayer G, Hoerauf A, Pfarr KM, and Famulok M. ADLOC – an aptamer-displacement assay based on luminescent oxygen channeling. Chemistry – a European journal, 2010, 16, 11100-7.

[54] Ahmed MSL and Mayer G. Evolution of specific RNA motifs derived from pan-protein interacting precursors. Bioorg. Med. Chem. Lett., 2010, 20, 3793-3796.

[53] Mayer G & Wulffen B. The Chemical Biology of Aptamers: Synthesis and applications. The Chemical Biology of Nucleic Acids, Wiley-VCH (Ed. Mayer G.), 2010, 377-400.

[52] Heckel A & Mayer G. Light-responsive nucleic acids for the spatio-temporal control of biological processes. The Chemical Biology of Nucleic Acids, Wiley-VCH (Ed. Mayer G.), 2010, 279-306.

[51] Mayer G, Ahmed MSL, Dolf A, Endl E, Knolle P, and Famulok M. Fluorescent-activated cell-sorting for aptamer SELEX with composite cells.Nat. Protocols2010, 5, 1993-2004.

[50] Lünse CE, Michlewski G, Hopp C, Rentmeister A, Cacerés J, Famulok M, and Mayer G. Apical-loop domain targeting modulates pri-miRNA processing. Angew. Chem. Int. Ed., 2009, 49, 4674-4677.

[49] Buff MC, Schäfer F, Wulffen B, Müller J, Pötzsch B, Heckel A, and Mayer G. Dependence of an aptamer on opposed terminal extension: improvement of light-regulation efficiency. Nucleic Acids Res.2010, 38, 2111-2118.

[48] Mayer G, Butzen S, Lohberger A, Pofahl M, and Heckel A. From selection to caged aptamers: identification of light-dependent ssDNA aptamers targeting cytohesin. Bioorg. Med. Chem. Lett., 2009, 19, 6561-6564.

[47] Müller J, Mayer G und Pötzsch B. Maßgeschneiderte Moleküle durch Aptamertechnologie. Deutsche Zeitschrift für Klinische Forschung2009, 9/10, 52-55.

[46] Mayer G. Tiny tags on RNA. ChemBioChem2009, 10, 2145-2146.

[45] Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Novak N, Beyer M, Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W, Glass C, Kurts C, and Knolle PA. The nuclear receptor PPARg selectively controls TH17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med.2009, 206, 2079-2089.

[44] Mayer G, Faulhammer D, Grättinger M, Fessele S, and Blind M. A RNA-based approach towards small molecule inhibitors. ChemBioChem2009, 10, 1993-1996.

[43] Mayer G. FACS-SELEX zur Identifikation zellspezifischer Aptamere. BIOspektrum2009, 3, 276-278.

[42] Siepmann M, Kumar S, Mayer G, and Walter J. Casein kinase 2 dependent phosphorylation of neprilysin regulates receptor tyrosine kinase signaling to Akt. PLoS one2010, 1, 5(10).

[41] Egler C, Brokemper O, Zabe-Kühn M, Mayer G, Oldenburg J, Schwaab R, and Albert T. Kinetic parameters of monoclonal antibodies ESH2, ESH4 and ESH8 on coagulation factor VIII and their influence on factor VIII activity.J. Mol. Recognit.2009, 22, 301-306.

[40] Karadeniz H, Erdem A, Mayer G, Famulok M, and Caliskan A. Electrochemical sensing of aptamer-protein interactions using magnetic particle assay and single-use sensor technology. Electroanalysis2009, 21, 1278-1284.

[39] Mayer G, Müller J, Mack T, Freitag DF, Höver T, Pötzsch B, and Heckel A. Differential regulation of protein sub-domain activity by caged bivalent ligands. ChemBioChem2009, 10, 654-657.

[38] Mayer G. The Chemical Biology of Aptamers. Angew. Chem. Int. Ed.,2009, 48, 2672-2689.

[37] Jayapal P, Mayer G, Heckel A, and Wennmohs F. Structure-Activity Relationships of a Caged Thrombin-Binding DNA Aptamer: Insight gained from molecular dynamics simulation studies. J. Struct. Biol.2009, 166, 241-250.

[36] Müller J, Isermann B, Dücker I, Salehi M, Meyer M, Friedrich M, Madhusudhan T, Oldenburg J, Mayer G, and Pötzsch B. An Exosite-specific ssDNA Aptamer Inhibits the Anticoagulant Functions of Activated Protein C and enhances Inhibition by Protein C Inhibitor. Chem. Biol., 2009, 16, 442-451.

[35] Hunsicker A, Steber M, Mayer G, Meitert J, Klotzsche M, Blind M, Hillen W, Berens C, and Suess B. An RNA Aptamer that Induces Transcription.Chem. Biol.2009, 16, 173-180.

[34] Mayer G and Famulok M. In vitro selection of conformational probes for riboswitches. Methods Mol. Biol., Springer Protocols, Humana Press Ltd. (in “Riboswitches: Methods and Protocols”, Vol. 540, Vol. Editor: Serganov A),2009, 291-300.

[33] Höver T and Mayer GIn vitro selection of ssDNA aptamers using biotinylated targets. Methods in Mol. Biol., Springer ProtocolsHumana Press Ltd. (in “Nucleic Acid and Peptide Aptamers: Methods and Protocols”, Vol. 535, Editor: Mayer G), 2009, 19-32.

[32] Müller J, Freitag D, Mayer G, and Pötzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J. Thromb. Haemost. 2008, 6, 2105-2112.

[31] Raddatz MSL, Dolf A, Endl E, Knolle P, Famulok M, and Mayer G. Enrichment of cell-targeting and population-specific aptamers by fluorescent-activated cell sorting. Angew. Chem. Int. Ed.2008, 47, 5190-5193.

[30] Mayer G, Wulffen B, Huber C, Brockmann J, Flicke B, Neumann L, Hafenbradl D, Klebl BM, Lohse MJ, Krasel C, and Blind M. A RNA molecule that specifically inhibits G-protein coupled receptor kinase 2 in vitroRNA,2008, 14, 524-534.

[29] Mayer G, Ackermann D, Kuhn N, and Famulok M. Construction of DNA architectures with RNA Hairpins. Angew. Chem. Int. Ed.2008, 47, 971-973.

[28] Müller J, El-Maarri O, Oldenburg J, Pötzsch B, and Mayer G. Monitoring the progression of the in vitro selection of nucleic acid aptamers by denaturing high-performance liquid chromatography. Anal. Bioanal. Chem.,2008, 390, 1033-1037.

[27] Rentmeister A*, Mayer G*, Kuhn N, and Famulok M. Secondary structures and functional requirements for thiM riboswitches fromDesulfovibrio vulgarisErwinia carotovora and Rhodobacter spheroidesBiol. Chem.2008, 389, 127-134. (*Joint first author)

[26] Müller J, Wulffen B, Pötzsch B, and Mayer G. Multi-domain targeting generates a high affinity thrombin-inhibiting bivalent aptamer.ChemBioChem, 2007, 8, 2223-2226.

[25] Mayer G und Famulok M. Nukleinsäuren im Drug Discovery Prozess: Aptamere als Therapeutika am Beispiel Pegaptanib und als Werkzeuge zur Wirkstoffsuche. Pharm. unserer Zeit2007, 36, 432-436.

[24] Famulok M, Hartig JS, and Mayer G. Functional Aptamers and Aptazymes in biotechnology, diagnostic, and therapy. Chem. Rev.2007,107, 3715-3743.

[23] Yamazaki S, Tan L, Mayer G, Song JN, Hartig J, Reuter S, Restle T, Kräusslich HG, Bajorath J, and Famulok M. Aptamer displacement identifies alternative small molecule target sites that escape viral resistance. Chem. Biol., 2007, 14, 804-812.

[22] Mayer G and Heckel A. Light-stimulated patterning of cells. ChemBioChem, 2007, 8, 857-858.

[21] Rentmeister A*, Mayer G*, Kuhn N, and Famulok M. Conformational changes in the expression domain of the thiM riboswitch. Nucleic Acids Res.,2007, 35, 3713-3722. (*Joint first author)

[20] Joachimi A, Mayer G, and Hartig J. A new anticoagulant-antidote pair: Control of thrombin activity by aptamers and porphyrins. J. Am. Chem. Soc.,2007,129, 3036-3037.

[19] Mayer G, Raddatz MSL, Grunwald JD, and Famulok M. RNA ligands that distinguish metabolite-induced conformations in the TPP riboswitch.Angew. Chem. Int. Ed.2007, 46, 557-560.

[18] Heckel A, Buff MC, Raddatz MSL, Müller J, Pötzsch B, and Mayer G. An anticoagulant with light triggered antidote activity. Angew. Chem. Int. Ed.,2006, 45, 6748-6750.

[17] Mayer G and Heckel A. Biologically active molecules with “light switch”.Angew. Chem. Int. Ed.2006, 45, 4900-4921.

[16] Famulok M and Mayer G. Aptamers in nanoland. Nature2006, 439, 666-668.

[15] Famulok M and Mayer G. Intramers for protein function analysis and drug discovery. In: The Aptamer Handbook - Functional Oligonucleotides and Their Applications. (Ed. S. Klussmann) VCH-Wiley, 2006.

[14] Mayer G and Famulok M. High-throughput-compatible assay for GlmS riboswitch metabolite dependence. ChemBioChem2006, 7, 602-604.

[13] Mayer G, Kröck L, Mikat V, Engeser M, and Heckel A. Light-induced formation of G-quadruplex DNA secondary structures. ChemBioChem2005, 6, 1966-1970.

[12] Heckel A and Mayer G. Light-regulated aptamer: An anti-thrombin aptamer with caged thymidine nucleobases. J. Am. Chem. Soc., 2005, 127, 822-23.

[11] Famulok M and Mayer G. Intramers and aptamers: Applications in protein function analyses and potential for drug screening. ChemBioChem,2005, 6, 19-26.

[10] Mayer G and Jenne A. Aptamers in research and drug development.BioDrugs2004, 6, 351-359.

[9] Najafi-Shoushtari S H, Mayer G, and Famulok M. Sensing complex regulatory networks by conformationally controlled hairpin ribozymes. Nucleic Acids Res., 2004, 15, 3212-3219.

[8] Mayer G, Graettinger M, and Blind M. Aptamers: Multifunctional tools for target validation and drug discovery. Drug Plus2003, 2, 6-10.

[7] Mayer G, Grättinger M, and Blind M. Nucleic Acid Biotools: Accelerating the Discovery of Lead Compounds. Screening – Trends in Drug Discovery,2002, 6, 35-37.

[6] Blind M, Faulhammer D, and Mayer G. Speeding up functional genomics by automated selection of intramers. American Genomics/Proteomics Technology, 2002, 7/8, 28-33.

[5] Schurer H, Stembera K, Knoll D, Mayer G, Blind M, Forster H, Famulok M, Welzel P, and Hahn U. Aptamers that bind to the antibiotic moenomycin A.Bioorg. Med. Chem. 2001 Oct;9(10):2557-63.

[4] Famulok M, Blind M, and Mayer G. Intramers as promising new tools in functional proteomics. Chem. Biol., 2001, 8, 931-939.

[3] Mayer G, Blind M, Nagel W, Böhm T, Knorr T, Jackson CL, Kolanus W and Famulok M. Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers. Proc. Natl. Acad. Sci. USA,2001, 98, 4961-4965.

[2] Famulok M, Mayer G, and Blind M. Nucleic Acid Aptamers - From selection in vitro to applications in vivo. Accounts of Chemical Research,2000, 33, 591-599.

[1] Famulok M and Mayer G. Aptamers as Tools in Molecular Biology and Immunology. In: Combinatorial Chemistry in Biology. Current Topics in Microbiology and Immunology (M. Famulok, C.-H. Wong, E.-L. Winnacker, Eds.), Springer Verlag, Heidelberg, 1999, 123-136.